| Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 (NCT07453602) | Arcutis Biotherapeutics, Inc. | 2026-03-02 |
| Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis (NCT07340216) | Arcutis Biotherapeutics, Inc. | 2025-12-15 |
| Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis (NCT06998056) | Arcutis Biotherapeutics, Inc. | 2025-06-09 |
| Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (NCT05028582) | Arcutis Biotherapeutics, Inc. | 2021-08-24 |
| Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) (NCT04845620) | Arcutis Biotherapeutics, Inc. | 2021-04-07 |
| Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo (NCT04811131) | Arcutis Biotherapeutics, Inc. | 2021-03-04 |
| Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) (NCT04746911) | Arcutis Biotherapeutics, Inc. | 2021-03-01 |
| Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (NCT04804605) | Arcutis Biotherapeutics, Inc. | 2021-02-25 |
| Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis (NCT04445987) | Arcutis Biotherapeutics, Inc. | 2020-06-12 |
| Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema (NCT04378569) | Arcutis Biotherapeutics, Inc. | 2020-04-20 |
| Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis (NCT04279119) | Arcutis Biotherapeutics, Inc. | 2020-03-10 |
| Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (NCT04286607) | Arcutis Biotherapeutics, Inc. | 2020-02-12 |
| Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema (NCT04156191) | Arcutis Biotherapeutics, Inc. | 2019-12-23 |
| Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (NCT04211363) | Arcutis Biotherapeutics, Inc. | 2019-12-20 |
| Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (NCT04211389) | Arcutis Biotherapeutics, Inc. | 2019-12-17 |
| Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis (NCT04091646) | Arcutis Biotherapeutics, Inc. | 2019-12-04 |
| Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis (NCT03916081) | Arcutis Biotherapeutics, Inc. | 2019-05-31 |
| Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis (NCT03764475) | Arcutis Biotherapeutics, Inc. | 2018-12-18 |
| The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis (NCT03638258) | Arcutis Biotherapeutics, Inc. | 2018-09-21 |
| Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis (NCT03392168) | Arcutis Biotherapeutics, Inc. | 2017-12-11 |